129 related articles for article (PubMed ID: 32012142)
1. Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy.
Li Z; Hu Y; Wang H; Wang M; Gu X; Ping Y; Zeng Q; Li H; Yan J; Yu Z
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):447-453. PubMed ID: 32012142
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
[TBL] [Abstract][Full Text] [Related]
5. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
6. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
7. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
8. Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
Loglio A; Iavarone M; Viganò M; Orenti A; Facchetti F; Cortinovis I; Lunghi G; Ceriotti F; Occhipinti V; Rumi M; Sangiovanni A; Colombo M; Lampertico P
Liver Int; 2019 Oct; 39(10):1964-1974. PubMed ID: 31323159
[TBL] [Abstract][Full Text] [Related]
9. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy.
Moon JC; Kim SH; Kim IH; Lee CH; Kim SW; Lee SO; Lee ST; Kim DG
Gut Liver; 2015 May; 9(3):395-404. PubMed ID: 25473072
[TBL] [Abstract][Full Text] [Related]
10. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
11. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
13. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
14. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
15. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.
Liang LY; Wong VW; Tse YK; Yip TC; Lui GC; Chan HL; Wong GL
Aliment Pharmacol Ther; 2019 Jun; 49(12):1509-1517. PubMed ID: 31025388
[TBL] [Abstract][Full Text] [Related]
16. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent.
Wang JH; Hu TH; Chen CH; Hung CH; Yen YH; Chang KC; Lu SN
Kaohsiung J Med Sci; 2019 Nov; 35(11):708-714. PubMed ID: 31430035
[TBL] [Abstract][Full Text] [Related]
17. [Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].
Zhao Z; Wang KF; Chen L; You QH; Wu YY; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):344-349. PubMed ID: 33979961
[No Abstract] [Full Text] [Related]
18. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
[TBL] [Abstract][Full Text] [Related]
20. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
